欢迎访问《中国临床药理学与治疗学》杂志官方网站,今天是 分享到:

中国临床药理学与治疗学 ›› 2009, Vol. 14 ›› Issue (6): 677-680.

• 临床药理学 • 上一篇    下一篇

甲磺酸罗哌卡因注射液病人体内药代动力学研究

王少华1, 赵艳1, 刘振胜1, 闫美兴1, 李志平1, 艾登斌2, 孙立新2   

  1. 1青岛市市立医院药物临床试验机构, 2麻醉科, 青岛 266011, 山东
  • 收稿日期:2009-03-11 修回日期:2009-06-15 出版日期:2009-06-26 发布日期:2020-10-27
  • 作者简介:王少华,女,主任药师,硕士生导师,主要从事新药临床试验及临床药学研究。Tel:0532-82789192 E-mail:wsh-pharm@yahoo.com.cn

Research on pharmacokinetics of ropivacaine methanesulfonate in patients

WANG Shao-hua1, ZHAO Yan1, LIU Zhen-sheng1, YAN Mei-xing1, LI Zhi-ping1, AI Deng-bin2, SUN Li-xin2   

  1. 1Base for Drug Clinical Trial, 2Department of Anesthesiology, Qingdao Municipal Hospital, Qingdao 266011, Shangdong, China
  • Received:2009-03-11 Revised:2009-06-15 Online:2009-06-26 Published:2020-10-27

摘要: 目的: 研究甲磺酸罗哌卡因注射液病人体内的药代动力学过程及药动学参数的性别差异。方法: 单剂量硬膜外给药15 mL, 采用HPLC 测定血浆中罗哌卡因的浓度。用DAS 软件计算其药代动力学参数。结果: 单剂量使用甲磺酸罗哌卡因注射液后男性和女性的消除半衰期t1/2β 分别为(4.050±2.548)、(2.088±0.135)h;吸收半衰期t1/2ka 分别为(0.085±0.045)、(0.107±0.069)h;达峰时间分别为(0.333±0.118)、(0.417±0.167)h;峰浓度分别为(1.066±0.135)、(1.113±0.317)mg/L;吸收程度(AUC0-tn, 统计矩法)分别为(2.856±0.321)、(2.369±0.386)mg·L-1·h;MRT0-tn 分别为(2.070±0.113)、(2.022±0.089)h 。结论: 本试验建立了甲磺酸罗哌卡因注射液血药浓度的固相萃取-HPLC 测定方法, 提供了单剂量使用的药动学参数, 试验结果表明各药动学参数性别间差异无统计学意义。

关键词: 甲磺酸罗哌卡因, 药代动力学, 性别差异, 血药浓度, 高效液相色谱法

Abstract: AIM: To study the pharmacokinetic profiles of ropivacaine methanesulfonate in patients and research the sex differences between these parameters. METHODS: 15 mL ropivacaine methanesulfonate injection was given when the patient had an epidural anesthesia.The concentrations of ropivacaine in plasma were determined by HPLC.The parameters of pharmacokinetics were calculated by DAS software. RESULTS: The pharmacokinetic parameters of male and female after administration with ropivacaine methanesulfonate injection were as follows:the t1/2β were (4.050±2.548) and (2.088±0.135)h;the t1/2Ka were (0.085±0.045) and (0.107±0.069)h;the tmax were (0.333±0.118) and (0.417±0.167)h; the Cmax were (1.066±0.135) and (1.113±0.317) mg/L;the AUC0-tn were (2.856±0.321) and (2.369±0.386)mg·L-1·h;the MRT0-tn were (2.070±0.113) and (2.022±0.089)h, respectively. CONCLUSION: The methodology to determine plasma concentration by HPLC and pharmacokinetic profiles of ropivacaine methanesulfonate injection were achieved. The results showed that there were no sex differences statistically between the pharmacokinetic parameters.

Key words: ropivacaine methanesulfonate, pharmacokinetics, sex difference, plasma concentration, high performance liquid chromatography

中图分类号: